Use of genome-wide association studies for drug repositioning (신약 재창출을 위한 유전 게놈 연관 연구)

Nat Biotechnol. 2012 Apr 10;30(4):317-20. doi: 10.1038/nbt.2151.

Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, Mooser V.

 

 

 

Nine hundred ninety-one GWAS-associated genes were selected from the GWAS catalog after two filtering steps (Supplementary Methods). These genes were eval!uated as potential drug targets for small molecules and biopharmaceuticals. one hundred fifty-five of these 991 genes were also targeted by drugs currently in pharmaceutical pipelines, as listed on the Pharmaprojects database, which has a total of 1,089 genes targeted by pipeline drugs. A total of 63 individual genes mapped to 52 different GWAS traits and drugs with the same or closely related indication to the GWAS traits (considered as matches). Conversely, 92 individual genes map to 51 GWAS traits and drugs with indications different from the GWAS traits (considered mismatches or potential drug-repositioning opportunities). Some genes are in both lists as they have multiple GWAS phenotypes that resulted in both a match to an existing indication and also a potentially novel indication.